BioSpace News Archive

Business

Paul Stead Joins Adaptimmune as Vice President of Business Development

Paul joins Adaptimmune, most recently, from Inovio Pharmaceuticals, Inc.

January 4, 2018
·
3 min read
Medigene AG: Expitope 2.0 Helps to Identify Safer Antigens for Immunotherapy of Cancer

MediGene AG announces that a scientific article has been published in the current issue of “BMC Cancer”.

January 4, 2018
·
4 min read
Drug Development

Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer

The Phase I/II trial was developed with extensive input from the Company’s Medical Advisory Board.

January 4, 2018
·
6 min read
LivaNova Commences Global RESTORE-LIFE Study for Treatment-Resistant Depression

LivaNova today announced the launch and enrollment of the first patient in the Global Prospective, Multi-center, Observational Post-market Study to Assess Short-, Mid- and Long-term Effectiveness and Efficiency of Vagus Nerve

January 4, 2018
·
4 min read
Business

Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-Versus-Host Disease

The study will be co-funded by Mount Sinai and Kamada.

January 4, 2018
·
7 min read
Policy

pSivida Granted Waiver by the FDA for NDA Filing Fee

The Company remains on track to file the Durasert NDA in early January.

January 4, 2018
·
4 min read
Policy

Vifor Pharma’s Veltassa Approved for Marketing in Switzerland for the Treatment of Hyperkalaemia

Veltassa is a sodium-free potassium binder approved for the treatment of hyperkalaemia in adults.

January 4, 2018
·
4 min read
Pharm Country

Helius Medical Technologies Announces Planned Five-for-One Reverse Stock Split

The Company’s common stock will begin trading on a split-adjusted basis on January 23, 2018 under the existing trading symbols.

January 4, 2018
·
5 min read
Drug Development

Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update

The company will concentrate its focus on rare (meeting the US FDA designation of an orphan disease.

January 4, 2018
·
13 min read
Portage Provides Update on Their Declaration of Stock Dividend of Biohaven Shares

Portage Biotech announces that trading in PBT.U was halted this morning pending clarification by the Canadian Securties Exchange of the Record Date and ex-distribution date.

January 4, 2018
·
3 min read